After a rough year in 2012, coal companies hope that they could bounce back a bit this year. In the latest deal between utilities and the coal industry, Duke Energy (NYSE: DUK ) has agreed to purchase between 1.7 million and 1.9 million short tons of coal from Peabody Energy (NYSE: BTU ) .
Currently, Peabody Energy is the lowest-cost producer of coal in the United States, which should be a critical fact now that natural gas prices are above $4 per MMBtu. It is well-diversified geographically and is the leading player in the cheapest basins in the U.S.
If you are an investor looking for another coal company that could capitalize from rising natural gas prices, turn to CONSOL Energy (NYSE: CNX ) . This is a company that owns the largest export facility on the East Coast and has turned the majority of its attention toward natural gas production, a move that is likely to provide a nice hedge against any continued domestic coal weakness.�
Hot Rising Stocks To Invest In 2015: WABCO Holdings Inc (WBC)
WABCO Holdings Inc. (WABCO) is a provider of electronic, mechanical and mechatronic products for the commercial truck, trailer, bus and passenger car manufacturers. The Company manufactures and sells control systems, including advanced braking, stability, suspension, transmission control and air compressing and processing systems. Its products are included in approximately two out of three commercial vehicles with advanced vehicle control systems and offered in niche applications in cars and sport utility vehicles (SUVs). WABCO develops, manufactures and sells advanced braking, stability, suspension and transmission control systems primarily for commercial vehicles. In September 2012, it acquired Ephicas.
The Company�� products include pneumatic anti-lock braking systems (ABS), electronic braking systems (EBS), automated manual transmission systems, air disk brakes, and a large variety of conventional mechanical products, such as actuators, air compressors and air control valves for heavy- and medium-sized trucks, trailers and buses. It also supplies advanced electronic suspension controls and vacuum pumps to the car and SUV markets in Europe, North America and Asia. The Company sells replacement parts, diagnostic tools, training and other services to commercial vehicle aftermarket distributors, repair shops, and fleet operators and provide remanufacturing services.
The Company�� key product groups include Actuator, Air Processing/Air Management System, Foundation Brake, Conventional Braking System, Electronic and Conventional Air Suspension Systems, Transmission Automation, Vehicle Electronic Architecture (VEA), and Vehicle Electronic Stability Control (ESC) and Roll Stability Support (RSS). WABCO sells its products primarily to four groups of customers worldwide: truck and bus (OEMs), trailer (OEMs), commercial vehicle aftermarket distributors for replacement parts and services, and major car manufacturers. Its customers include Daimler, Volvo, Ashok Leyland, BMW, China! National Heavy Truck Corporation (CNHTC), Cummins, Fiat (Iveco), Hino, Hyundai, Krone, MAN Nutzfahrzeuge AG (MAN), Meritor, Meritor WABCO (a joint venture), Paccar (DAF Trucks N.V. (DAF), Kenworth, Leyland and Peterbilt), First Automobile Works, Otto Sauer Achsenfabrik (SAF), Scania, Schmitz Cargobull AG, TATA Motors and ZF Friedrichshafen AG (ZF).
The Company competes with Knorr-Bremse, Haldex, Bosch, Continental and Siemens-VDO.
Advisors' Opinion:- [By Adam Haigh]
Westpac Banking Corp. (WBC) and Commonwealth Bank of Australia, the two biggest Australian lenders, each slid at least 1 percent as minutes from a central bank meeting highlighted concern about business conditions. ICBC, the world�� largest lender by market value, sank 2.1 percent in Hong Kong. Tokyo Electric Power Co. (9501) gained 12 percent, taking this month�� rise to 90 percent.
- [By Yoshiaki Nohara]
Australia�� S&P/ASX 200 Index retreated 0.7 percent, led by energy and financial shares. Woodside Petroleum Ltd. (WPL), Australia�� second-biggest oil and gas producer, dropped 2 percent to A$34.67. Westpac Banking Corp. (WBC), Australia�� No. 2 lender by market value, shed 1.2 percent to A$27.47.
Hot Rising Stocks To Invest In 2015: Associated Estates Realty Corp (AEC)
Associated Estates Realty Corporation (AEC), incorporated on July 29, 1993, is an integrated, self-administered and self-managed equity real estate investment trust (REIT). As of December 31, 2012, the Company�� portfolio consisted of 52 properties containing 13,950 units located in 10 states. The Company operates in one segment: multifamily properties. The Company is focused on multifamily ownership, operation, acquisition, development, construction, disposition and property management activities. Its multifamily properties provided approximately 99.4% of its consolidated revenue. In 2012, the Company acquired four properties. Three of the properties, totaling 760 units, are located in the Raleigh/Durham submarket and the fourth is a 396-unit property located in Dallas, Texas. In addition, in 2012, it acquired land for development of an apartment community in Los Angeles, California that also includes a building containing approximately 78,800 total square feet of office and retail space. In 2012, it sold six properties containing 1,356 units, one in Georgia, one in Central Ohio and four in Western Michigan. During the three years ended December 31, 2012, it acquired 11 multifamily properties.
The Company�� primary source of income is rental revenue. The Company�� subsidiary, Merit Enterprises, Inc. (Merit), is a general contractor and construction manager, which acts as its in-house construction division. In March 2012, the partnership acquired a 2.5 acre parcel of land in Bethesda, Maryland.
Advisors' Opinion:- [By Nathan Slaughter]
Shocking new data reveals that of the 5.5 million new households that will be formed between now and 2016, an estimated 3.8 million, or nearly 70%, will be renters, not homeowners according to Jeffrey Friedman, CEO of apartment REIT Associated Estates Realty (Nasdaq: AEC).
5 Best Sliver Stocks To Buy For 2015: VelaTel Global Communications Inc (VELA.PK)
VelaTel Global Communications Inc, formerly China Tel Group, Inc. (ChinaTel), incorporated on September 19, 2005, is engaged in the business, which combines its engineering and deployment, its equity funding relationships, its vendor partnership, radio frequency spectrum, fiber optic cable and concession rights assets acquired through a subsidiary or a joint venture relationship to create and operate wireless broadband access (WBA) networks worldwide. It offers Internet access, voice, video, and data services to the subscribers of various WBA networks it operate. The Company�� secondary business is to distribute products and services used in connection with WBA networks, specifically hydrogen fuel cells used as a back-up power source for certain transmission equipment, and devices and services. As of December 31, 2011, it holds investments or contracts in ten projects: the VelaTel Peru Network; the GBNC Network; the VN Tech Fuel Cell Business; the Exclusive Services Agreement with NGSN; the Exclusive Services Agreement with Aerostrong; the Sino Crossings Fiber Joint Venture; Zapna; the Novi-Net Network; the Montenegro Connect Network and the VeratNet Network. In April 2012, it acquired Herlong Investments Limited and its operating subsidiaries, Novi-Net and Montenegro Connect. In April 2012, it signed and closed a stock purchase agreement to acquire a 75% equity interest in Zapna, ApS. In November 2012, the Company acquired 100% of interest in China Motion Telecom (HK) Limited.
The Company sells prepaid and postpaid plans, and branded consumer devices using VelaTel Peru�� brand name GO MOVIL. Chinacomm holds licenses and permits from China to build and operate a 3.5-gigahertz wireless broadband telecommunications network (Chinacomm Network) in 29 cities in China. These licenses run through February 2013. Phase 1 of the Chinacomm Network consisted of the deployment of the Chinacomm Network in the 12 cities of Beijing, Shanghai, Guangzhou, Shenzhen, Qindao, Nanjing, Chongqing, Harbin, X! ian, Xiamen, Wuhan and Kunming.. Portions of the Chinacomm Network are operational in Beijing, Shanghai and Shenzhen. Perusat provides local and international long-distance telephone services, including fixed line and voice over Internet protocol (IP) services, to approximately 6,500 customers in nine cities in Peru (Lima, Arequipa, Chiclayo, Trujillo, Piura, Santa, Cusco, Ica and Huanuco). Based on its status as a licensed telephone operator, Perusat has been granted a license in the 2.5-gigahertz spectrum covering these cities, other than Lima and its surrounding metropolitan area.
The Company contracted with Chinacomm to acquire a 49% equity interest in ChinaComm Limited (Chinacomm Cayman). Trussnet Capital Partners (HK), Ltd. (TCP) acquired a 49% interest in Chinacomm Cayman. Trussnet Dalian leased Yunji equipment required in the deployment of the Chinacomm Network and provide technical and management services to Yunji for the procurement, installation and optimization of the equipment.
The Compets with GBNC, VN Tech, NGSN, Aerostrong, Sino Crossings, Novi-Net, Montenegro Connect and VeratNet.
Advisors' Opinion:- [By Alan Brochstein]
Matula, who is currently a SVP for LiveDeal (LIVE), has a history of association with penny stock failures. An interesting angle is his tie to a lawyer in Las Vegas, Michael Balabon, who purports to have two separate practices, including a bankruptcy/divorce practice and an employment law practice who has acted as Registered Agent for many of these companies. I was unable to reach anyone at either office on several occasions. In any event, Balabon is the registered agent for PLPL. Coincidentally, he served in that role for NVLX as well as well as all of the former subsidiaries and partners the firm used (the new Medical Marijuana Sciences subsidiary too). Recall that the predecessor to PLPL was Diamond Ranch, and Balabon was the RA there as well. Matula has served in I.R. roles for perpetual failures like VelaTel Global (VELA.PK).
Hot Rising Stocks To Invest In 2015: Genetic Technologies Ltd (GENE)
Genetic Technologies Limited provides genetic testing services. It offers a range of DNA based genetic tests for cancer predisposition, including breast cancer, ovarian cancer, bowel cancer, and uterine cancer; neurogenetic diagnostic assays; and gene testing for gene related disorders. The company also provides forensics tests, such as presumptive and confirmatory testing, individual DNA profiling, species identification, and animal forensic testing; paternity tests, which include antenatal, deceased estate, grandparent, immigration, legal paternity, non-legal paternity, sibling, twins, and Y-Chromosome DNA testing, as well as DNA profiling; and personal DNA testing comprising sports performance and ancestry gene testing. In addition, it offers animals� tests consisting of disease testing, breed identification, coat color, and forensic DNA testing, as well as DNA clinical services; and plant tests, including genomic and Xpress sequencing services. Further, the company is involved in the out-licensing of its intellectual property relating to non-coding DNA; and research and development activities in the areas of genetics and related fields. It operates in Australia, the United States, China, Canada, and Switzerland. The company was formerly known as Duketon Goldfields N.L. and changed it name to Genetic Technologies Limited in August 2000 as a result of the change in business from mining to biotechnology. Genetic Technologies Limited is headquartered in Fitzroy, Australia
Advisors' Opinion:- [By Holly LaFon]
Eugene (Gene) Abegg is arguably the greatest banker nobody has ever heard of. In fact, Abegg could have been cast as a crusty version of George Bailey of the Bailey Building and Loan Association in Frank Capra's It's a Wonderful Life.
- [By John Udovich]
The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer with the overall costs of the disease topping $126 billion annually ��meaning there is a big market for small cap cancer diagnostic stocks like Rosetta Genomics Ltd. (NASDAQ: ROSG), Genetic Technologies Limited (NASDAQ: GENE) and MetaStat Inc (OTCBB: MTST) just in the US alone without considering global cancer figures. After all, catching and doing something about cancer early on is critical to increase survival rates and bring down the cost of treatment. With that in mind, here are three small cap cancer diagnostic stocks helping to lead the fight to diagnose and stop cancer:
Hot Rising Stocks To Invest In 2015: Raymond James Financial Inc (RJF)
Raymond James Financial, Inc. (RJF) is a financial services holding company whose subsidiaries are engaged in various financial services businesses predominantly in the United States of America and Canada. At September 30, 2011, its principal subsidiaries include Raymond James & Associates, Inc. (RJ&A), Raymond James Financial Services, Inc. (RJFS), Raymond James Financial Services Advisors, Inc. (RJFSA), Raymond James Ltd. (RJ Ltd.), Eagle Asset Management, Inc. (Eagle), and Raymond James Bank, FSB (RJ Bank). All of these subsidiaries are wholly owned by RJF. In April 1, 2011, the Company acquired Howe Barnes Hoefer & Arnett (Howe Barnes). The Company operates through eight business segments: Private Client Group, Capital Markets, Asset Management, RJ Bank, Emerging Markets, Securities Lending, Proprietary Capital and various corporate activities combined in the Other segment. In April 2012, Regions Financial Corporation sold Morgan Keegan & Company, Inc. and related affiliates to RJF.
PRIVATE CLIENT GROUP
The Company provides securities transaction and financial planning services to approximately two million client accounts through the branch office systems of RJ&A, RJFS, RJFSA, RJ Ltd. and Raymond James Investment Services Limited (RJIS), a joint venture in the United Kingdom. Its financial advisors offer a range of investments and services, including both third-party and products, and a variety of financial planning services. The Company charges sales commissions or asset-based fees for investment services it provides to its Private Client Group clients based on established schedules. Varying discounts may be given, generally based upon the client's level of business, the trade size, service level provided, and other relevant factors. During the fiscal year ended September 30, 2011 (fiscal 2011), the portion of revenues from this segment that the Company considers recurring include sources, such as asset-based fees, including mutual fund and annuity trailing commissions, ! and interest income and represented approximately 61% of the Private Client Group's total revenues. Its financial advisors offer a number of professionally managed load mutual funds, as well as a selection of no-load funds. RJ&A and RJFS maintain dealer sales agreements with distributors of mutual fund shares sold through broker-dealers.
The Company�� principal subsidiary, RJ&A, is the full service brokerage and investment firm headquartered in the state of Florida and with over 220 locations throughout the United States, is a retail brokerage firms in the country. RJ&A is a self-clearing broker-dealer engaged in most aspects of securities distribution, trading, investment banking and asset management. RJ&A also offers financial planning services for individuals and provides clearing services for RJFS, RJFSA, other affiliated entities and several unaffiliated broker-dealers. RJFS is an independent contractor brokerage firms in the United States., is a member of Financial Industry Regulatory Authority (FINRA) and Securities Investors Protection Corporation (SIPC), but is not a member of any exchanges. Financial advisors affiliated with RJFS may offer their clients all products and services offered through RJ&A, including investment advisory products and services which are offered through its affiliated registered investment advisor, RJFSA. RJ Ltd. is its Canadian broker-dealer subsidiary, which is engaged in both retail and institutional distribution and investment banking. RJ Ltd. is a member of the Toronto Stock Exchange (TSX) and the Investment Industry Regulatory Organization of Canada (IIROC). Its United States broker-dealer subsidiary is a member of FINRA and SIPC.
CAPITAL MARKETS
Capital Markets activities consist primarily of equity and fixed income products and services. Its institutional clients are serviced by institutional equity departments of RJ&A and RJ Ltd.; the RJ&A fixed income department; RJ&A�� European offices; Raymond James Financial Intern! ational, ! Ltd, an institutional UK broker-dealer, and Raymond James European Securities, Inc., a joint venture, in which the Company hold a controlling interest. The Company charges commissions on equity transactions based on trade size and the amount of business conducted annually with each institution. Fixed income commissions are based on trade size and the characteristics of the specific security. Some European and United States offices also provide services to high net worth clients. RJ Ltd. has approximately 40 institutional equity sales and trading professionals servicing predominantly Canadian, United States and European institutional investors from offices in Canada and Europe.
Trading equity securities involves the purchase and sale of securities from and to its clients or other dealers. RJ&A makes markets in over 900 common stocks. The RJ Ltd. trading desks not only support client activity, but also take positions that are closely monitored within well defined limits. RJ Ltd. also provides specialist services in approximately 150 TSX listed common stocks. RJ&A trades both taxable and tax-exempt fixed income securities. The taxable and tax-exempt RJ&A fixed income traders purchase and sell corporate, municipal, government, government agency, and mortgage-backed bonds, asset-backed securities, preferred stock and certificates of deposit from and to its clients or other dealers.
Fixed income investment banking includes debt underwriting and public finance activities. The syndicate department consists of professionals who coordinate the marketing, distribution, pricing and stabilization of lead and co-managed equity underwritings. In addition to lead and co-managed offerings, this department coordinates the firm's syndicate and selling group activities in transactions managed by other investment banking firms. Raymond James Tax Credit Funds, Inc. (RJTCF) is the general partner or managing member in a number of limited partnerships and limited liability companies. These partnershi! ps and li! mited liability companies invest in real estate project entities that qualify for tax credits under Section 42 of the Internal Revenue Code.
ASSET MANAGEMENT
The Company�� Asset Management segment includes the operations of Eagle, the Eagle Family of Funds (Eagle Funds), the asset management operations of RJ&A (AMS), Raymond James Trust, and other fee-based programs. The majority of the revenue for this segment is generated by the investment advisory fees related to asset management services for individual investment portfolios and mutual funds. Investment advisory fees are also earned on assets held in managed and non-managed programs. Eagle Fund Distributors, Inc. (EFD), a wholly owned subsidiary of Eagle, is a registered broker-dealer engaged in the distribution of the Eagle Funds. The Eagle Funds utilize unaffiliated sub-advisors for the Capital Appreciation Fund and International Equity Fund. The Small Cap Growth Fund, Mid Cap Growth Fund, Growth and Income Fund, Large Cap Core Fund, Mid Cap Stock Fund, Investment Grade Bond Fund, and Small Cap Core Value Fund are managed by Eagle.
AMS
AMS manages several investment advisory programs which maintain an approved list of investment managers, provide asset allocation model portfolios, establish custodial facilities, monitor performance of client accounts, provide clients with accounting and other administrative services, and assist investment managers with certain trading management activities. In addition, AMS offers additional managed accounts managed within fee based asset allocation platforms under its Freedom accounts and other managed programs. Freedom�� investment committee manages portfolios of mutual funds, exchange traded funds and separately managed account models on a discretionary basis. AMS also provides certain services for their non-managed fee-based programs (Passport, Ambassador and other non-managed programs). They provide performance reporting, research, sales, accounting, trad! ing and o! ther administrative services. Client fees are based on the individual account or relationship size and may also be dependent on the type of securities in the accounts.
Raymond James Trust, National Association, (RJT) provides personal trust services primarily to existing clients of its broker-dealer subsidiaries. Portfolio management of trust assets can be subcontracted to its asset management operations. This subsidiary had a total of approximately $2 billion in client assets at September 30, 2011, including nearly $120 million in the donor-advised charitable foundation known as the Raymond James Charitable Endowment Fund.
RJ BANK
RJ Bank is a federally chartered savings bank, regulated by the Office of the Comptroller of the Currency (OCC), which provides corporate, residential and consumer loans, as well as Federal Deposit Insurance Corporation (FDIC) insured deposit accounts, to clients of our broker-dealer subsidiaries and to the general public. RJ Bank is active in corporate loan syndications and bank participations as well as purchases residential whole loan packages to hold for investment. RJ Bank generates revenue principally through the interest income earned on loans and investments, which is offset by the interest expense it pays on client deposits and on its borrowings.
RJ Bank�� assets include C&I loans, commercial and residential real estate loans, as well as consumer loans that were purchased or originated by RJ Bank. Corporate loans represent approximately 75% of RJ Bank�� loan portfolio of which 90% are Shared National Credits (SNC) or other large syndicated loans. RJ Bank purchases and originates corporate loans secured by corporate assets, commercial and industrial (C&I) loans, commercial and residential real estate loans, as well as consumer loans, all of which are funded primarily by cash balances swept from the investment accounts of our broker-dealer subsidiaries��clients.
EMERGING MARKETS
Raymond! James In! ternational Holdings, Inc. (RJIH), through its subsidiaries, has interests in operations in Latin American countries including Argentina, Uruguay and Brazil. Through these entities it operates securities brokerage, investment banking, asset management and equity research businesses. In fiscal 2011, approximately 75% of this segments��investment banking revenues arose from one client.
SECURITIES LENDING
This segment conducts its business through the borrowing and lending of securities from and to other broker-dealers, financial institutions and other counterparties. The Company conducts these activities as an intermediary. Securities Lending will also loan customer marginable securities held in a margin account containing a debit to counterparties. The borrower of the securities puts up a cash deposit on which interest is earned. The lender in turn receives cash and pays interest. These cash deposits are adjusted daily to reflect changes in the current market value of the underlying securities. Additionally, securities are borrowed from other broker-dealers to facilitate RJ&A�� clearance and settlement obligations. The net revenues of this securities lending business are the interest spreads generated.
PROPRIETARY CAPITAL
This segment consists of its principal capital and private equity activities, including various direct and third-party private equity and merchant banking investments; Raymond James Employee Investment Funds I and II (the EIF Funds), and a private equity fund which we sponsor-Raymond James Capital Partners, L.P. As of September 30, 2011, certain of its merchant banking investments include an investment in a manufacturer of crime investigation and forensic supplies, an event photography business, and an indirect investment in an allergy immunotherapy testing and treatment supply company.
Advisors' Opinion:- [By Omar Venerio]
The company has a current ROE of 13.13% which is higher than the one exhibited by its peers JPMorgan Chase (JPM) and Raymond James (RJF). In general, analysts consider ROE ratios in the 15-20% range as representing attractive levels for investment. It is very important to understand this metric before investing and it is important to look at the trend in ROE over time.
- [By Eric Volkman]
The joint book-running managers of the issue are Raymond James Financial (NYSE: RJF ) unit Raymond James & Associates, Royal Bank of Canada's (NYSE: RY ) RBC Capital Markets, and the Securities divisions of Credit Suisse and Deutsche Bank (NYSE: DB ) . The sale is expected to close on May 28.
Hot Rising Stocks To Invest In 2015: Genomic Health Inc (GHDX)
Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.
Oncotype DX Platform
The Company�� Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient'! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.
Oncotype DX Breast Cancer Test
To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.
In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.
Oncotype DX Colon Cancer Test
The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and recurrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.
The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.
Advisors' Opinion:- [By John Udovich]
Small cap genomics stocks Rosetta Genomics Ltd (NASDAQ: ROSG), Genomic Health, Inc (NASDAQ: GHDX) and CollabRx Inc (NASDAQ: CLRX) are at the forefront of genomics testing�or research. I should mention that Wikipedia defines genomics�as a�discipline in genetics that applies recombinant DNA, DNA sequencing methods and bioinformatics to sequence, assemble and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism). A 2013 Booz Allen Hamilton report on the sector noted that in�2011, the US genetic and genomic clinical testing market size was estimated to be $5.9 billion while the�number of available tests has grown substantially from 1,680 just 4 years ago to 2,886 in 2012.
- [By Keith Speights]
Genetic testing stands out as one current example of how scientific advances can help reduce medical costs. Genomic Health (NASDAQ: GHDX ) makes genetic diagnostic tests for�breast, colon, and prostate cancer. Half of the patients diagnosed with prostate cancer each year actually have a very low risk of the cancer progressing. However, 90% of these low-risk patients still undergo surgery or radiation -- at a cost of tens of thousands of dollars per patient. Genomic Health's genetic test helps identify which patients really need more extensive treatment and holds the potential to reduce overall costs.
- [By Jon C. Ogg]
Genomic Health Inc. (NASDAQ: GHDX) was downgraded to Underperform from an already cautious Neutral and the price target was cut to $33 from $36 by Bank of America�Merrill Lynch.
- [By John Udovich]
Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:
Hot Rising Stocks To Invest In 2015: PostRock Energy Corporation(PSTR)
PostRock Energy Corporation, an integrated independent energy company, engages in the acquisition, exploration, development, production, and transportation of oil and natural gas in the United States. It operates in two segments, Oil and Gas Production, and Natural Gas Pipelines. The Oil and Gas Production segment primarily focuses on the development of coal bed methane in the Cherokee basin and the Marcellus Shale in Appalachian Basin, as well as has oil properties in Central Oklahoma. As of December 31, 2009, it had approximately 51.9 billion cubic feet equivalent (Bcfe) of estimated net proved reserves; development rights to approximately 516,184 net acres; and operated approximately 2,849 gross wells in the Cherokee Basin. It also had approximately 44,507 net acres of oil and natural gas producing properties with estimated proved reserves of 18.9 Bcfe and approximately 498 gross wells in Appalachian Basin; and had 65 gross wells, development rights to approximately 1,4 80 net acres, and estimated net proved reserves, 3.9 Bcfe in Central Oklahoma. The Natural Gas Pipelines segment involves in transporting, gathering, treating, and processing natural gas. It owns and operates a natural gas gathering pipeline networks of approximately 2,173 miles in the Cherokee Basin and 183 miles in the Appalachian Basin; and a 1,120 mile interstate natural gas pipeline, which transports natural gas from northern Oklahoma and western Kansas to the metropolitan Wichita and Kansas City markets. The company is headquartered in Oklahoma City, Oklahoma.
Advisors' Opinion:- [By Eric Volkman]
LeBlanc is a veteran energy industry CFO. He has filled that role at East Resources -- now a unit of Royal Dutch Shell (NYSE: RDS-A ) -- as well as�PostRock Energy (NASDAQ: PSTR ) , and Range Resources, among others.
Hot Rising Stocks To Invest In 2015: Bio-Reference Laboratories Inc.(BRLI)
Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. It offers various chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology, pap smears, tissue pathology, and other tissue analysis. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems. In addition, it operates a Web-based connectivity portal solution for laboratories and physicians to provide laboratory ordering and results to physician customers. The company provides its services directly to physicians, geneticists, hospitals, clinics, and correctional and other health facilities. Bio-Refe rence Laboratories, Inc. was founded in 1981 and is headquartered in Elmwood Park, New Jersey.
Advisors' Opinion:- [By Ben Levisohn]
As a result, LabCorp has dropped 11% to $87.79 and has helped drag down competitors like Quest Diagnostics (DGX), and BioReference Laboratories (BRLI).
- [By Geoff Gannon] strong>DreamWorks (DWA)
Read these reports. Look for something that might have interested me. Why would Geoff look at DNB, Chuck E. Cheese, etc.? What got him interested in the stock? Do I see the same thing?
Whenever possible, also read the quarterly earnings call transcripts. You can listen to them too. But it�� easier if you read them and listen to them.
Just listening is a bad idea.
Whenever I can get a transcript of anything ��even Warren Buffett�� appearance on CNBC ��I��l keep a copy of the transcript even when I have a copy of the video (or audio). You can refer back to a transcript easily. You can highlight. You can take notes.
Taking Notes
Now, you are doing those things when reading an annual report, right?
You never just sit down and read an annual report. You always sit down with a pen, a highlighter, a pad of paper, and a calculator. Use the margins of a 10-K ��or your pad of paper ��to jot down notes. Ask questions. Do calculations.
If you ever see a 10-K after I��e read it ��it�� not very white anymore. There�� lots of stuff written in the margins. Mostly it�� questions I was asking myself. But it�� also calculations of numbers the company does not provide.
Numbers to Know
So, for example, in a bank�� 10-K I always write down:
路 Deposits per share
路 Deposits per branch
路 Cost of deposits
路 Texas Ratio
You can actually look up the Texas Ratio of any bank here. And some banks calculate and report cost of deposits the way I like to think about it. But, it�� not common for banks to report deposits per branch ��although small banks will sometimes mention (perhaps in the shareholder letter) what their biggest branch has in deposits. Others may mention how quickly new branches achieved a deposit milestone.
Those are the kinds of numbers I write in the margins of a bank�� 10-K. There will be questions like: ��hy is e
- [By GuruFocus]
An example here is Bio Reference Lab (BRLI). This is a company with a simple business, strong balance sheet and the Predictability Rank of 5-Star. At the price of $19, BRLI was in the top of the Buffett-Munger Screener. But the stock price quickly dropped to below $12 in November 2011. At that point, the company announced a share buyback. The CEO, CFO and COO also bought shares in December at $14 a share. Since then the stock price has doubled.
Hot Rising Stocks To Invest In 2015: Continental Resources Inc. (CLR)
Continental Resources, Inc. engages in the exploration, development, and production of crude oil and natural gas primarily in the north, south, and east regions of the United States. The company primarily sells its oil and natural gas production to end users, as well as to midstream marketing companies or oil refining companies at the lease. As of December 31, 2011, its estimated proved reserves were 508.4 million barrels of crude oil equivalent, with estimated proved developed reserves of 205.2 million barrels of crude oil equivalent. The company had interests in 3,255 wells and served as the operator of 2,082 of these wells. Continental Resources, Inc. was founded in 1967 and is headquartered in Enid, Oklahoma.
Advisors' Opinion:- [By Lee Jackson]
Continental Resources Inc. (NYSE: CLR) was recently upgraded and makes the list of top names to buy. The company is one of the top names in the Bakken shale and the analysts are expecting a slow, but steady increase in production levels. The Merrill Lynch price target is posted at $145, and the consensus is at $131.45. Continental closed Friday at $106.91. A move to the target represents a 36% gain for investors.
- [By Matt DiLallo]
Kodiak is paying $660 million to privately held Liberty Resources to add 42,000 net acres to the company's position in the Bakken, which will boost Kodiak's total position in the play to 196,000 net acres. That's a substantial increase as the deal boosts Kodiak's acreage by more than 30%. While Kodiak is still about a million acres behind top Bakken leaseholder Continental Resources (NYSE: CLR ) , the deal really does vault Kodiak's presence in the play. Even better, as you can see from the map below, these acres are close to Kodiak's current operations:
- [By Matt DiLallo]
The price of oil varies between drillers, as well costs and capital structures also vary in the industry, which can make drilling more profitable for some and a struggle for others. Top Bakken producer�Continental Resources (NYSE: CLR ) is one of the play's lowest-cost producers. The company's operated wells cost about $9.2 million to complete last year whereas its non-operated wells cost more than $11.3 million to complete. Looking ahead, the company is hoping to knock another million dollars of its completion costs at operated wells this year. The story is similar with smaller Bakken driller, Kodiak Oil and Gas (NYSE: KOG ) ; however, its overall numbers are much higher. Last year the company spent around $11 million to drill a well, and it expects to get that number down below $10 million per well this year. This is a case were Continental can afford to keep growing even if oil prices dip, while Kodiak might need to put the brakes on its production growth plans.�
No comments:
Post a Comment